Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 6, 1999, Pages 1031-1035

  Fost, David A ^a   Leung, Donald Y M ^a,b   Martin, Richard J ^a   Brown, Eleanor E ^a   Szefler, Stanley J ^a,b   Spahn, Joseph D ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Asthma; Clarithromycin; Glucocorticoids; Methylprednisolone; Pharmacok inetics; Prednisone

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENTIATION; HUMAN; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032784404     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70175-2     Document Type: Article

References (26)

1. 1. Kaplan MA, Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. In: Welch H, Marti-Ibauez F, editors. Antibiotic annual 1958-1959. New York: Interscience Publishers; 1959. p. 273-6.
2. 2. Berkovich S, Millian SJ, Snyder RD. The association of viral and mycoplasma infections with recurrence of wheezing in the asthmatic child. Ann Allergy 1970;28:43-9.
3. 3. Seggev JS, Lis I, Siman-Tov R, Gutman R, Abu-Samara H, Schey G, et al. Mycoplasma pneumoniae is a frequent cause of exacerbation of bronchial asthma in adults. Ann Allergy 1986;57:263-5.
4. 4. Alvarez J, Surs W, Leung DYM, Iklé D, Gelfand EW, Szefler SJ. Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol 1992;89:714-21.
5. 5. Ong KS, Grieco MH, Rosner W. Enhancement by oleandomycin of the inhibitor effect of methylprednisolone on phytohemagglutinin-stimulated lymphocytes. J Allergy Clin Immunol 1978;62:115-8.
6. 6. Greos LS, Szefler SJ, Larsen GL, Irvin CG, Hill MR. Troleandomycin reduces airway inflammation [abstract]. Am Rev Respir Dis 1990;141:A933.
7. 7. Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Antiallergic activity of roxithromycin inhibition of interleukin-5 production from mouse T-lymphocytes. Life Sci 1993;52:25-30.
8. 8. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980;66:447-51.
9. 9. LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983;72:34-9.
10. 10. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993;147:398-404.
11. 11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
12. 12. Ebling WF, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone and methylprednisolone hemisuccinate: absence of effects of troleandomycin on ester hydrolysis. J Chromatogr 1984;305:271-80.
13. 13. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983;16:203-16.
14. 14. Kraft M, Cassell GH, Henson JE, Bettinger CM, Duffy LB, Rex MD, et al. The potential for mycoplasma to be an etiologic factor in chronic asthma [abstract]. Am J Respir Crit Care Med 1996;153:A412.
15. 15. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970;45:146-2.
16. 16. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991;99:670-3.
17. 17. Hahn DL. Intracellular pathogens and their role in asthma: Chlamydia pneumonie in adult patients. Eur Respir Rev 1996;6:224-30.
18. 18. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990;65:37-45.
19. 19. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
20. 20. Jusko WJ, Ludwig EA. Corticosteroids. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver (WA): Applied Pharmacokinetics; 1992. p. 27.1-27.34.
21. 21. Khalafallah N, Jusko WJ. Tissue distribution of prednisolone in the rabbit. J Pharmcol Exp Ther 1984;229:719-25.
22. 22. Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991;88:147-65.
23. 23. Ebling WF, Milsap RL, Szefler SJ, Jusko WJ. 6α-methylprednisolone and 6α-methylprednisone plasma protein binding in humans and rabbits. J Pharm Sci 1986;75:760-3.
24. 24. Vichyanond P, Irvin CG, Larsen GL, Szefler SJ, Hill MR. Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol 1989;84:867-73.
25. 25. Greos LS, Vichyanond P, Bloedow DC, Irvin CG, Larsen GL, Szefler SJ, et al. Methylprednisolone achieves greater concentrations in the lung than prednisolone: a pharmacokinetic analysis. Am Rev Respir Dis 1991;144:586-92.
26. 26. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone elimination in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987;42:424-32.